Risk of serious infections and malignancies with anti-TNF antibody theraphy in rheumatoid arthritis [4]

JAMA

Volumn 296, Issue 18, 2006, Pages 2203-

  Hochman, David ^a   Wolff, Bruce ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CANCER RISK; CLINICAL TRIAL; COLON CANCER; HUMAN; INFECTION; INFECTION RISK; LETTER; META ANALYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

EID: 33750709212     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
2. Bleday R, Lee E, Jessurun J, Heine J, Wong D. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum. 1993;36:908-912.
3. Narumi S, Roberts JP, Edmond JC, Lake J, Ascher NL. Liver transplantation for sclerosing cholangitis. Hepatology. 1995;22:451-457.
4. Higashi H, Yanaga K, Marsh JW, Tzakis A, Kakizoe S, Starzl TE. Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Hepatology. 1990;11:477-480.
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.